藥物安全檢測市場規模、佔有率及成長分析（依生命週期、類型、部署、最終用戶和地區）－2025 年至 2032 年產業預測

2023 年藥物安全檢測市場規模價值 75 億美元，預計將從 2024 年的 80.1 億美元成長到 2032 年的 135.6 億美元，預測期間（2025-2032 年）的複合年成長率為 6.8%。

全球藥物安全檢測市場正在經歷強勁成長，這得益於對病人安全的日益關注、嚴格的監管要求以及製藥業的不斷擴張。主要促進因素是，隨著新治療方法開發日益複雜以及藥品消費量不斷增加，對藥物警戒的需求也日益增加。隨著監管機構執行更嚴格的指導方針，製藥公司被迫加強藥物安全檢測業務，進一步刺激市場擴張。此外，慢性病的快速增加凸顯了藥物安全檢測在識別和減輕藥物不良反應方面的關鍵作用，從而提高了患者安全性並降低了醫療保健成本。醫療保健提供者和監管機構共同努力優先考慮有效的藥物安全檢測系統，旨在顯著改善醫療保健結果和患者健康。

目錄

介紹

• 調查目的
• 研究範圍
• 定義

調查方法

• 資訊採購
• 二次資料和一次資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分機會分析

市場動態與展望

• 市場概覽
• 市場規模
• 市場動態
  • 促進因素和機會
  • 限制與挑戰
• 波特的分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 主要投資機會
• 市場生態系統
• 市場吸引力指數（2024年）
• PESTEL分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 監管格局
• 案例研究
• 技術進步
• 貿易分析

藥物安全檢測市場規模（依生命週期和複合年成長率） (2025-2032)

• 市場概覽
• 臨床前
• 第一階段
• 第二階段
• 第三階段
• 第四階段

藥物安全檢測市場規模（按類型及複合年成長率）（2025-2032）

• 市場概覽
• 自發性報告
• 增強型 ADR 報告
• 有針對性和自發性的報道
• 群組心臟事件記錄器
• EHR挖掘

藥物安全檢測市場規模（按部署和複合年成長率） (2025-2032)

• 市場概覽
• 內部
• 合約外包

藥物安全檢測市場規模（按最終用戶和複合年成長率） (2025-2032)

• 市場概覽
• 合約研究組織（CRO）
• 製藥和生物技術公司
• 其他

藥物安全檢測市場規模（按地區）及複合年成長率（2025-2032）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業市場定位（2024年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市場佔有率分析（2024年）
• 主要企業簡介
  • 公司詳情
  • 產品系列分析
  • 公司分部佔有率分析
  • 收益與前一年同期比較對比（2022-2024 年）

主要企業簡介

• Accenture（Ireland）
• IQVIA Inc.（United States）
• Cognizant（United States）
• IBM Corporation（United States）
• Capgemini（France）
• ITClinical（Portugal）
• ICON plc（Ireland）
• TAKE Solutions Limited（India）
• Parexel International Corporation（United States）
• Wipro（India）
• United BioSource LLC（United States）
• BioClinica Inc.（Clario）（United States）
• ClinChoice（formerly FMD K&L）（United States）
• Linical Americas（United States）
• Science 37 Holdings, Inc.（United States）
• LEO Pharma（Denmark）
• argenx（Belgium）
• Purisys（United States）

結論和建議

PharmaCovigilances Market size was valued at USD 7.5 billion in 2023 and is poised to grow from USD 8.01 billion in 2024 to USD 13.56 billion by 2032, growing at a CAGR of 6.8% during the forecast period (2025-2032).

The global pharmacovigilance market is witnessing robust growth, propelled by an increasing emphasis on patient safety, stringent regulatory demands, and the expanding pharmaceutical sector. Key drivers include the heightened necessity for drug safety monitoring amid the complexity of new therapeutic developments and rising drug consumption. As regulatory agencies enforce more rigorous guidelines, pharmaceutical companies are compelled to enhance their pharmacovigilance practices, further stimulating market expansion. Additionally, the surge in chronic disease prevalence underscores the critical role of pharmacovigilance in identifying and mitigating adverse drug reactions, thereby enhancing patient safety and reducing healthcare costs. The combined efforts of healthcare providers and regulatory bodies to prioritize effective pharmacovigilance systems aim to improve healthcare outcomes and patient welfare significantly.

Top-down and bottom-up approaches were used to estimate and validate the size of the Pharmacovigilances market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Pharmacovigilances Market Segments Analysis

Global PharmaCovigilances Market is segmented by Life Cycle, Type, Deployment, End User and region. Based on Life Cycle, the market is segmented into Pre-clinical, Phase I, Phase II, Phase III and Phase IV. Based on Type, the market is segmented into Spontaneous Reporting, Intensified ADR Reporting, Targeted Spontaneous Reporting, Cohort Event Monitoring and EHR Mining. Based on Deployment, the market is segmented into In-house and Contract Outsourcing. Based on End User, the market is segmented into Contract Research Organizations (CROs), Pharmaceutical & Biotechnology Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Pharmacovigilances Market

The global pharmacovigilance market is experiencing significant growth due to the rising prevalence of adverse drug reactions (ADRs) worldwide. As pharmaceutical product usage continues to grow, so does the likelihood of individuals facing unexpected side effects. Pharmacovigilance is essential for monitoring and reporting these ADRs, enabling early detection, risk assessment, and the implementation of necessary actions to protect patient health. The increasing need for effective pharmacovigilance services and solutions is driven by the urgency to manage the escalating rates of ADRs, thereby contributing to the market's expansion and highlighting its vital importance in ensuring drug safety.

Restraints in the Pharmacovigilances Market

A notable challenge within the global pharmacovigilance market is the limited awareness and insufficient infrastructure present in developing regions. These areas struggle to create and implement comprehensive pharmacovigilance systems. The lack of understanding about the importance of pharmacovigilance, coupled with weak regulatory frameworks and resource limitations, hampers the integration of effective practices. Additionally, the presence of inadequate infrastructure, a shortage of trained personnel, and poor data management systems contribute to obstacles for the advancement of the pharmacovigilance market in these regions, ultimately impeding its growth and effectiveness in ensuring drug safety.

Market Trends of the Pharmacovigilances Market

The pharmacovigilance market is witnessing robust growth driven by the escalating consumption and development of pharmaceuticals, significantly increasing the necessity for monitoring drug safety. With high-profile recalls like Aurobindo Pharma's 2022 Quinapril withdrawal, the industry is under pressure to manage adverse drug reactions effectively. This has led regulatory authorities to demand more extensive medical information, fueling market expansion. Additionally, partnerships such as IQVIA's collaboration with NRx Pharmaceuticals signal a strategic shift towards comprehensive pharmacovigilance services, enhancing compliance and patient safety. As awareness of drug-related risks rises, the pharmacovigilance sector is poised for sustained growth, underscoring its critical role in healthcare.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technological Advancement
• Trade Analysis

Global PharmaCovigilances Market Size by Life Cycle & CAGR (2025-2032)

• Market Overview
• Pre-clinical
• Phase I
• Phase II
• Phase III
• Phase IV

Global PharmaCovigilances Market Size by Type & CAGR (2025-2032)

• Market Overview
• Spontaneous Reporting
• Intensified ADR Reporting
• Targeted Spontaneous Reporting
• Cohort Event Monitoring
• EHR Mining

Global PharmaCovigilances Market Size by Deployment & CAGR (2025-2032)

• Market Overview
• In-house
• Contract Outsourcing

Global PharmaCovigilances Market Size by End User & CAGR (2025-2032)

• Market Overview
• Contract Research Organizations (CROs)
• Pharmaceutical & Biotechnology Companies
• Others

Global PharmaCovigilances Market Size & CAGR (2025-2032)

• North America (Life Cycle, Type, Deployment, End User)
  • US
  • Canada
• Europe (Life Cycle, Type, Deployment, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Life Cycle, Type, Deployment, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Life Cycle, Type, Deployment, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Life Cycle, Type, Deployment, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• Accenture (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IQVIA Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cognizant (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• IBM Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Capgemini (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ITClinical (Portugal)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TAKE Solutions Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel International Corporation (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Wipro (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• United BioSource LLC (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioClinica Inc. (Clario) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ClinChoice (formerly FMD K&L) (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Linical Americas (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Science 37 Holdings, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• LEO Pharma (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• argenx (Belgium)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Purisys (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations